Rhumbline Advisers Buys 11,025 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Rhumbline Advisers increased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 556,255 shares of the biotechnology company’s stock after purchasing an additional 11,025 shares during the quarter. Rhumbline Advisers owned about 0.29% of BioMarin Pharmaceutical worth $36,563,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. New York State Teachers Retirement System increased its stake in shares of BioMarin Pharmaceutical by 4.0% in the 4th quarter. New York State Teachers Retirement System now owns 106,138 shares of the biotechnology company’s stock valued at $6,976,000 after buying an additional 4,057 shares during the period. Asset Management One Co. Ltd. boosted its holdings in BioMarin Pharmaceutical by 0.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 76,785 shares of the biotechnology company’s stock valued at $5,136,000 after acquiring an additional 283 shares during the last quarter. Savant Capital LLC increased its position in BioMarin Pharmaceutical by 106.6% in the fourth quarter. Savant Capital LLC now owns 28,936 shares of the biotechnology company’s stock worth $1,902,000 after purchasing an additional 14,930 shares during the period. Stoneridge Investment Partners LLC raised its holdings in BioMarin Pharmaceutical by 151.7% during the 4th quarter. Stoneridge Investment Partners LLC now owns 10,545 shares of the biotechnology company’s stock worth $693,000 after purchasing an additional 6,355 shares during the last quarter. Finally, WCM Investment Management LLC lifted its position in BioMarin Pharmaceutical by 3.5% during the 4th quarter. WCM Investment Management LLC now owns 17,540 shares of the biotechnology company’s stock valued at $1,148,000 after purchasing an additional 595 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on BMRN shares. William Blair cut shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 30th. Citigroup dropped their target price on shares of BioMarin Pharmaceutical from $93.00 to $81.00 and set a “neutral” rating for the company in a research report on Wednesday, October 30th. UBS Group raised their price target on BioMarin Pharmaceutical from $104.00 to $106.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Wolfe Research initiated coverage on BioMarin Pharmaceutical in a report on Friday, November 15th. They issued an “outperform” rating and a $95.00 price objective for the company. Finally, StockNews.com upgraded BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 11th. Seven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $94.20.

BioMarin Pharmaceutical Stock Performance

BMRN opened at $64.86 on Wednesday. The company has a market capitalization of $12.36 billion, a price-to-earnings ratio of 38.84, a P/E/G ratio of 0.57 and a beta of 0.28. The business’s 50-day moving average price is $64.82 and its two-hundred day moving average price is $71.24. BioMarin Pharmaceutical Inc. has a 1 year low of $60.63 and a 1 year high of $94.85. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.